About: Synaffix     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Organisation, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon
http://dbpedia.demo.openlinksw.com/c/6QALUqFR2A

Synaffix is a Dutch biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs) which are used primarily in the treatment of cancer. ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are designed to target only the cancer cells and spare normal, healthy tissues. Most recently, Synaffix has secured granted patents covering its ADC technology that offer end-to-end protection on resulting therapeutic products through at least 2035.

AttributesValues
rdf:type
rdfs:label
  • Synaffix (en)
rdfs:comment
  • Synaffix is a Dutch biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs) which are used primarily in the treatment of cancer. ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are designed to target only the cancer cells and spare normal, healthy tissues. Most recently, Synaffix has secured granted patents covering its ADC technology that offer end-to-end protection on resulting therapeutic products through at least 2035. (en)
foaf:name
  • Synaffix BV (en)
foaf:homepage
name
  • Synaffix BV (en)
foaf:depiction
  • http://commons.wikimedia.org/wiki/Special:FilePath/Synaffix-LogoRGB.jpeg
  • http://commons.wikimedia.org/wiki/Special:FilePath/Synaffix_aerial_shot.jpeg
dct:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
thumbnail
foundation
founders
  • Prof. Dr. Floris van Delft and Dr. Sander van Berkel (en)
homepage
image caption
  • Synaffix R&D facility (en)
industry
location city
location country
logo
  • Synaffix-LogoRGB.jpeg (en)
type
  • Private (en)
has abstract
  • Synaffix is a Dutch biotechnology company headquartered in the Netherlands that has developed a clinical-stage platform technology for antibody-drug conjugates (ADCs) which are used primarily in the treatment of cancer. ADCs utilize potent small molecule payloads, similar to those used for chemotherapy, but are designed to target only the cancer cells and spare normal, healthy tissues. The proprietary technology of Synaffix was developed to enable the treatment of a wide variety of cancer types and is designed to significantly enhance the effectiveness while also improving the safety and tolerability of these targeted cancer therapeutics. Benchmarking studies consistently demonstrate that, with a given antibody and ADC payload, ADCs produced using Synaffix technology display significantly enhanced effectiveness and significantly enhanced tolerability and safety versus all 3-major clinical-stage ADC technologies. The most advanced ADC that employs Synaffix technology will be given to the first cancer patients in 2018. In October 2016, Synaffix made the first public disclosure of its commercial license agreement with ADC Therapeutics Sarl (ADCT). Under the terms of the Agreement, ADCT may develop one or multiple products using Synaffix technology. In October 2017, Synaffix announced that ADC Therapeutics had triggered a second target-specific license under their existing deal from 2016 to develop a second ADC product candidate using Synaffix technology. Beyond this, ADC Therapeutics retains an option to take a limited number of additional single-target licenses for their potential future programs. Most recently, Synaffix has secured granted patents covering its ADC technology that offer end-to-end protection on resulting therapeutic products through at least 2035. Synaffix was founded in 2010 based on inventions made in the field of copper-free click chemistry at the Radboud University in Nijmegen. Subsequently, this chemistry was combined with the use of enzymatic antibody modification in order to facilitate the generation of targeted cancer therapeutics. (en)
gold:hypernym
prov:wasDerivedFrom
page length (characters) of wiki page
founding year
industry
foaf:isPrimaryTopicOf
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git147 as of Sep 06 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 57 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software